Dispersible bosentan tablet

Details Dispersible bosentan tablet Dispersible bosentan tablet

2011-06-14

2011-06-14

Wax, Robert A (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C514S269000

Reexamination Certificate

active

07959945

ABSTRACT:
The invention relates to dispersible tablets comprising the compound 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4-yl]-benzenesulfonamide.

REFERENCES:
patent: 2003/0087911 (2003-05-01), Adams et al.
patent: 2003/0232845 (2003-12-01), Dahanukar et al.
patent: 2007-7028463 (2009-08-01), None
“Tracleer [bosentan] 62.5 mg and 125 mg film-coated tablets,” FDA Medwatch, [online], Oct. 6, 2003, pp. 1-21.
Rosenzweig et al, “Reply” Journal of the American College of Cardiology, Elsevier, NY, vol. 47, No. 9, May 2006, pp. 1914-1915.
Handbook of Pharmaceutical Excipients, Third Edition, Arthur H. Kibbe, American Pharmaceutical Association, Washington, USA and Parmaceutical Press, London.
L. Lachman et al., “The Theory and Practice of Industrial Pharmacy,” 3rd Edition, 1986.
Remington's Pharmaceutical Sciences, 13th Ed., (Mack Publ. Co., 1970) or later editions.

Affiliated with

Also associated with

Rating

Dispersible bosentan tablet does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dispersible bosentan tablet, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dispersible bosentan tablet will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2669236